In recent years, the excellent curative effect of CD19‐specific chimeric antigen receptor
(CAR) T‐cell therapy has brought hope to patients with relapsing or refractory B‐cell …

Adoptive transfer of T cells genetically modified to express chimeric antigen receptors
(CARs) targeting CD19 has produced impressive results in treating patients with B-cell …

Adoptive immunotherapy with chimeric antigen receptor-modified (CAR)-T cells is a rapidly
growing therapeutic approach to treating patients with refractory cancer, with over 100 …

As we expand our acumen of the intricacies of hematological malignancies at a genetic and
cellular level, we have paved the way in advancing novel targeted therapeutic avenues such …

Chimeric antigen receptor (CAR)–modified T cells have revolutionized the treatment of
CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous …

Chimeric antigen receptor (CAR)-T cell therapy is undeniably a promising tool in combating
various types of hematological malignancies. However, it is not yet optimal and a significant …

CD19 chimeric antigen receptor T-cell (CAR-T) therapy is efficacious for refractory/relapsed
(R/R) B-cell hematological malignancies, yet relapse due to CD19 antigen escape remains …

Chimeric antigen receptor (CAR) T-cell immunotherapy has achieved unprecedented
efficacy in the treatment of chemotherapy-resistant or refractory B-cell malignancies …

Chimeric antigen receptor (CAR) modified T cell therapy has revolutionized the treatment of
relapsed and refractory hematological malignancies. Through targeting of the CD19 antigen …

Introduction Chimeric antigen receptor (CAR)-modified T-cell therapy has revolutionized the
treatment of relapsed/refractory B-cell malignancies including acute lymphoblastic leukemia …